Inside MoonLake’s raid on Merck KGaA’s inflammatory disease hopeful sonelokimabSwiss biotech MoonLake Immunotherapeutics has emerged with what it hopes is one of the hottest drugs in inflammatory Share XInside MoonLake’s raid on Merck KGaA’s inflammatory disease hopeful sonelokimabhttps://pharmaphorum.com/views-and-analysis/inside-moonlakes-raid-on-merck-kgaas-inflammatory-disease-hopeful-sonelokimab/
MoonLake launches, licensing in Merck KGaA’s Cosentyx challenger sonelokimabThere’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a Share XMoonLake launches, licensing in Merck KGaA’s Cosentyx challenger sonelokimabhttps://pharmaphorum.com/news/moonlake-launches-licensing-in-merck-kgaas-cosentyx-challenger-sonelokimab/
